Myeloproliferative neoplasms: trials for referral
237 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Myeloproliferative neoplasms·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
237 trials shown
Phase 1/22 sites
RecruitingUnited States
NCT06523556
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Uma Borate
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT06303193
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 4130 sites
RecruitingArgentina, Austria, Bulgaria, Brazil, Canada, China
NCT04877522
Asciminib Roll-over Study
Novartis Pharmaceuticals
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 2227 sites
RecruitingCanada, Puerto Rico, United States
NCT05554406
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per World Health Organization (WHO) criteria”
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 3208 sites
RecruitingArgentina, Austria, Australia, Belgium, Bulgaria, Brazil
NCT07623161
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Takeda
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3173 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT07357727
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3192 sites
RecruitingAustria, Australia, Belgium, Canada, Switzerland, Czechia
NCT07623200
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Incyte Corporation
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07468916
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2/35 sites
RecruitingCanada, Israel, United States
NCT07722611
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Merck Sharp & Dohme LLC
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 146 sites
RecruitingCanada, China, Germany, Spain, France, United Kingdom
NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 233 sites
RecruitingCanada, Germany, Spain, France, Italy, United States
NCT06517875
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
GlaxoSmithKline
Registry updated 4 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 27 sites
RecruitingUnited States
NCT07886801
A Study of Ropeg-Interferon in People With Polycythemia Vera
Memorial Sloan Kettering Cancer Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02727803
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07909733
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
University of Wisconsin, Madison
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 154 sites
RecruitingAustralia, Belgium, Canada, Germany, Spain, France
NCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 3115 sites
RecruitingAustria, Australia, Brazil, Czechia, Germany, Spain
NCT07429266
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Ono Pharmaceutical Co., Ltd.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07904871
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06265584
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 125 sites
RecruitingAustralia, Spain, France, Italy, United States
NCT07469891
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics Incorporated
Pre-treatment window Registry sentence: “Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.”
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07883382
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingUnited States
NCT07447817
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
John Mascarenhas
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT05535764
AlloHCT With PegINFa for Myelofibrosis
University of Utah
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 136 sites
RecruitingAustralia, United States
NCT07849231
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Damora Therapeutics
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 232 sites
RecruitingUnited States
NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT07281781
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
University of California, Irvine
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 355 sites
RecruitingUnited Kingdom
NCT04116502
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
University of Birmingham
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingAustralia
NCT07891533
Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera
AN2 Therapeutics, Inc
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingUnited States
NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT07020533
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States116 open trials
- Italy42 open trials
- France40 open trials
- China30 open trials
- Spain28 open trials
- Germany27 open trials
- United Kingdom21 open trials
- Canada21 open trials
- Australia18 open trials
- Poland15 open trials
- Belgium15 open trials
- Japan11 open trials
- Netherlands11 open trials
- Hungary10 open trials
- South Korea10 open trials
- Czechia9 open trials
- Austria9 open trials
- Bulgaria7 open trials
- Greece7 open trials
- Romania7 open trials
- Israel6 open trials
- Taiwan5 open trials
- Brazil5 open trials
- Türkiye5 open trials
- Portugal4 open trials
- Denmark4 open trials
- Malaysia4 open trials
- Russia3 open trials
- Switzerland3 open trials
- New Zealand3 open trials
- Hong Kong3 open trials
- Croatia3 open trials
- India2 open trials
- Ireland2 open trials
- Sweden2 open trials
- Georgia2 open trials
- Thailand2 open trials
- Serbia2 open trials
- Puerto Rico2 open trials
- Lebanon1 open trial
- Slovakia1 open trial
- Argentina1 open trial
- Vietnam1 open trial
- Chile1 open trial
- Colombia1 open trial
- Mexico1 open trial
- Norway1 open trial
- Saudi Arabia1 open trial
- Armenia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
Catania, Italy
13 trials · 10 publications · ROR
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
18 trials · 6 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
32 trials · 38 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis
NCT07925632 · No phase · China
Source: ClinicalTrials.govOpened for recruitment
NCT07623161 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT06987058 · Phase 2 · Spain, France, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 · Phase 2 · Italy
Source: ClinicalTrials.govOpened for recruitment
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
NCT06605586 · Phase 1/2 · Germany, Netherlands
Source: ClinicalTrials.govOpened for recruitment
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
NCT05037760 · Phase 2 · Australia, Brazil, Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 4
NCT04877522 · Phase 4 · Argentina, Austria, Bulgaria, Brazil, Canada, China
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04562870 · Phase 2 · China, Spain, France, Greece, Italy, Poland
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513 · Phase 1/2 · Germany, Spain, France, United Kingdom, Italy, United States
Source: ClinicalTrials.govClosed for recruitment
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
NCT05037760 · Phase 2 · Australia, Brazil, Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govClosed for recruitment
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
NCT06605586 · Phase 1/2 · Germany, Netherlands
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07623161 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil
Source: ClinicalTrials.govClosed for recruitment
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 · Phase 2 · Italy
Source: ClinicalTrials.govStopped early
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
NCT02530034 · Phase 1 · United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 15 Oct 2026
Stopped early15 participants
NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given: FDA Clinical Hold
Phase 1/2Ended 8 Sept 2026
Completed84 participants
NCT04455841
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Phase 1Ended 4 Sept 2026
Completed8 participants
NCT07444268
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
Phase 2Ended 30 Jun 2026
Stopped early36 participants
NCT06397313
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Reason given: Sponsor decision
Phase 2Ended 30 Jun 2026
Completed83 participants
2024-511688-27-00
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN)
Phase 2Ended 11 Jun 2026
Withdrawn before start0 participants
NCT06597734
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Reason given: PI request
Phase 1/2Ended 3 Jun 2026
Phase 2Ended 2 Jun 2026
Completed50 participants
NCT05143957
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Phase 1Ended 1 Jun 2026
Withdrawn before start0 participants
NCT03939585
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given: Lack of funding
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Phase 2Ended 4 May 2026
No phaseEnded 29 Apr 2026
No phaseEnded 31 Mar 2026
Phase 2Ended 24 Mar 2026
Completed270 participants
NCT01810588
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Phase 4Ended 26 Feb 2026
No phaseEnded 1 Feb 2026
Phase 2Ended 22 Jan 2026
Completed61 participants
NCT02251821
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 2Ended 20 Jan 2026
Completed121 participants
NCT01787487
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. · Journal of hematology & oncology, 2026
Phase 2Ended 15 Jan 2026
Show more
Phase 2Ended 9 Jan 2026
Completed25 participants
NCT05177211
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Phase 2Ended 4 Jan 2026
Withdrawn before start0 participants
NCT05927012
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Reason given: Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.
No phaseEnded 31 Dec 2025
Completed2115 participants
NCT02775383
The National Myelodysplastic Syndromes (MDS) Study
- Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex. · American journal of hematology, 2026
- A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study. · Blood advances, 2026
Phase 1/2Ended 30 Dec 2025
Stopped early21 participants
NCT06245941
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
Reason given: Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
Phase 3Ended 17 Oct 2025
Completed21 participants
NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
No phaseEnded 14 Oct 2025
Completed237 participants
NCT07839858
A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
Phase 2Ended 9 Oct 2025
No phaseEnded 20 Aug 2025
Phase 1Ended 12 Aug 2025
Completed32 participants
NCT06598956
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
Phase 1Ended 12 Aug 2025
Stopped early9 participants
NCT06388759
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
Reason given: This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Phase 1Ended Jul 2025
Withdrawn before start0 participants
NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Reason given: Medigene transfered all rights to a new Sponsor
No phaseEnded Jul 2025
Completed10 participants
NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Phase 3Ended 28 Jul 2025
Completed202 participants
NCT03952039
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
No phaseEnded 22 Jul 2025
Completed68 participants
NCT05419648
Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
Phase 2Ended 10 Jul 2025
Completed20 participants
NCT05558696
A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)
Phase 1/2Ended 9 Jul 2025
Phase 1/2Ended 30 Jun 2025
Completed16 participants
NCT05120570
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Phase 1Ended 24 Jun 2025
Phase 2Ended 19 May 2025
Completed44 participants
NCT03427866
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
Phase 2Ended 9 May 2025
Withdrawn before start0 participants
NCT06619522
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
Reason given: 0 participant accrual
Phase 2Ended 3 May 2025
Stopped early150 participants
NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given: Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.
Phase 2Ended 23 Apr 2025
Phase 2Ended 18 Apr 2025
Completed46 participants
NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
No phaseEnded 31 Mar 2025
Completed70 participants
NCT07319026
Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis
Phase 2Ended 24 Mar 2025
Completed78 participants
NCT02988466
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 1/2Ended 19 Mar 2025
Completed31 participants
NCT05153343
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative
Phase 1Ended 10 Mar 2025
Stopped early9 participants
NCT05609942
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Reason given: Terminated - alignment of strategic priorities
Phase 2Ended 5 Mar 2025
Stopped early17 participants
NCT03627403
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Reason given: PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.
Phase 1/2Ended 27 Feb 2025
Stopped early12 participants
NCT03878199
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Reason given: The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.
Phase 2Ended 29 Jan 2025
Completed191 participants
NCT03222609
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
- Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE). · Hematological oncology, 2026
- Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies. · Leukemia & lymphoma, 2026
Phase 3Ended 29 Jan 2025
Phase 1/2Ended 9 Jan 2025
Completed336 participants
NCT02158858
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Phase 1Ended 3 Jan 2025
Stopped early12 participants
NCT05127174
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Reason given: Did not advance to Phase 2
Phase 2Ended 19 Dec 2024
Completed135 participants
NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 3Ended 25 Nov 2024
Stopped early252 participants
NCT04551066
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Reason given: The study was terminated due to futility.
No phaseEnded 13 Nov 2024
Completed30 participants
NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Phase 1/2Ended Oct 2024
Withdrawn before start0 participants
NCT04629651
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Reason given: PI discretion
Phase 2Ended 30 Oct 2024
No phaseEnded 30 Oct 2024
No phaseEnded 18 Oct 2024
Stopped early2013 participants
NCT01688011
Connect® Myeloid Disease Registry
Reason given: Business objectives have changed
Not medical advice. fetched 11 Nov 2026